CA
RMD icon

Capitolis Advisors’s ResMed RMD Stock Holding History

Capitolis Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,163
Closed -$1.6M – 423
2021
Q4 		$1.6M Hold
6,163
– – 0.01% 436
2021
Q3 		$1.58M Sell
6,163
-2,279
-27% -$623K 0.01% 306
2021
Q2 		$2.08M Hold
8,442
– – 0.02% 264
2021
Q1 		$1.64M Hold
8,442
– – 0.03% 265
2020
Q4 		$1.79M Buy
+8,442
New +$1.68M 0.03% 331

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Capitolis Advisors's RMD Position: Q1 2022 in Review

Capitolis Advisors sold out of ResMed (RMD) in Q1 2022, closing a stake of 6,163 shares — an estimated $1.6M sold.

Capitolis Advisors first reported a position in RMD in Q4 2020 and held it in 5 quarters. The position peaked at $2.08M in Q2 2021. 682 funds tracked by Wall St. Rank hold RMD as of Q1 2022.

  • Capitolis Advisors reported no remaining ResMed position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 6,163 ResMed shares in Q1 2022, an estimated $1.6M.
  • Capitolis Advisors first reported a position in ResMed in Q4 2020 and held it in 5 quarters.
  • Capitolis Advisors's ResMed position peaked at $2.08M in Q2 2021.
  • 682 funds tracked by Wall St. Rank held ResMed as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.